

## SOME AROMATIC AMINES AND RELATED COMPOUNDS

VOLUME 127

This publication represents the views and expert opinions of an IARC Working Group on the Identification of Carcinogenic Hazards to Humans, which met remotely, 25 May–12 June 2020

LYON, FRANCE - 2021

IARC MONOGRAPHS  
ON THE IDENTIFICATION  
OF CARCINOGENIC HAZARDS  
TO HUMANS

# CONTENTS

---

<b>NOTE TO THE READER</b> .....	<b>1</b>
<b>LIST OF PARTICIPANTS</b> .....	<b>3</b>
<b>PREAMBLE</b> .....	<b>7</b>
<b>A. GENERAL PRINCIPLES AND PROCEDURES</b> .....	<b>7</b>
1. Background.....	7
2. Objective and scope.....	8
3. Selection of agents for review .....	9
4. The Working Group and other meeting participants.....	9
5. Working procedures.....	11
6. Overview of the scientific review and evaluation process .....	12
7. Responsibilities of the Working Group.....	14
<b>B. SCIENTIFIC REVIEW AND EVALUATION</b> .....	<b>15</b>
1. Exposure characterization .....	15
2. Studies of cancer in humans.....	18
3. Studies of cancer in experimental animals.....	23
4. Mechanistic evidence .....	26
5. Summary of data reported.....	29
6. Evaluation and rationale.....	30
References.....	35
<b>GENERAL REMARKS</b> .....	<b>39</b>
<b><i>ORTHO</i>-ANISIDINE AND <i>ORTHO</i>-ANISIDINE HYDROCHLORIDE</b> .....	<b>45</b>
1. Exposure Characterization .....	45
1.1 Identification of the agent .....	45
1.2 Production and use .....	46
1.3 Measurement and analysis.....	47
1.4 Occurrence and exposure.....	47
1.5 Regulations and guidelines .....	49

2. Cancer in Humans .....	50
Case reports .....	50
3. Cancer in Experimental Animals .....	50
3.1 Mouse .....	50
3.2 Rat .....	54
3.3 Synthesis .....	55
4. Mechanistic Evidence .....	56
4.1 Absorption, distribution, metabolism, and excretion .....	56
4.2 Evidence relevant to key characteristics of carcinogens .....	58
4.3 Data relevant to comparisons across agents and end-points .....	71
4.4 Other relevant evidence .....	71
5. Summary of Data Reported .....	72
5.1 Exposure characterization .....	72
5.2 Cancer in humans .....	72
5.3 Cancer in experimental animals .....	72
5.4 Mechanistic evidence .....	72
6. Evaluation and Rationale .....	73
6.1 Cancer in humans .....	73
6.2 Cancer in experimental animals .....	74
6.3 Mechanistic evidence .....	74
6.4 Overall evaluation .....	74
6.5 Rationale .....	74
References .....	74

<b>ORTHO-NITROANISOLE .....</b>	<b>81</b>
1. Exposure Characterization .....	81
1.1 Identification of the agent .....	81
1.2 Production and use .....	82
1.3 Measurement and analysis .....	82
1.4 Occurrence and exposure .....	82
1.5 Regulations and guidelines .....	83
2. Cancer in Humans .....	84
3. Cancer in Experimental Animals .....	84
3.1 Mouse .....	84
3.2 Rat .....	90
3.3 Synthesis .....	92
4. Mechanistic Evidence .....	93
4.1 Absorption, distribution, metabolism, and excretion .....	93
4.2 Evidence relevant to key characteristics of carcinogens .....	94
4.3 Other relevant evidence .....	102
5. Summary of Data Reported .....	102
5.1 Exposure characterization .....	102
5.2 Cancer in humans .....	102
5.3 Cancer in experimental animals .....	102
5.4 Mechanistic evidence .....	103

---

6. Evaluation and Rationale . . . . .	104
6.1 Cancer in humans . . . . .	104
6.2 Cancer in experimental animals . . . . .	104
6.3 Mechanistic evidence . . . . .	104
6.4 Overall evaluation . . . . .	104
6.5 Rationale . . . . .	104
References . . . . .	105
<b>ANILINE AND ANILINE HYDROCHLORIDE . . . . .</b>	<b>109</b>
1. Exposure Characterization . . . . .	109
1.1 Identification of the agent . . . . .	109
1.2 Production and use . . . . .	110
1.3 Measurement and analysis . . . . .	114
1.4 Occurrence and exposure . . . . .	115
1.5 Regulations and guidelines . . . . .	138
1.6 Quality of exposure assessment in key epidemiological studies . . . . .	141
2. Cancer in Humans . . . . .	147
2.1 Cohort studies . . . . .	148
2.2 Case-control studies . . . . .	161
2.3 Case reports and case series . . . . .	163
2.4 Evidence synthesis for cancer in humans . . . . .	166
3. Cancer in Experimental Animals . . . . .	168
3.1 Mouse . . . . .	177
3.2 Rat . . . . .	178
3.3 Hamster . . . . .	182
3.4 Rabbit . . . . .	182
3.5 Synthesis . . . . .	183
4. Mechanistic Evidence . . . . .	183
4.1 Absorption, distribution, metabolism, and excretion . . . . .	183
4.2 Evidence relevant to key characteristics of carcinogens . . . . .	188
4.3 Data relevant to comparisons across agents and end-points . . . . .	219
4.4 Other relevant evidence . . . . .	220
5. Summary of Data Reported . . . . .	221
5.1 Exposure characterization . . . . .	221
5.2 Cancer in humans . . . . .	221
5.3 Cancer in experimental animals . . . . .	222
5.4 Mechanistic evidence . . . . .	222
6. Evaluation and Rationale . . . . .	224
6.1 Cancer in humans . . . . .	224
6.2 Cancer in experimental animals . . . . .	224
6.3 Mechanistic evidence . . . . .	224
6.4 Overall evaluation . . . . .	224
6.5 Rationale . . . . .	224
References . . . . .	224

---

<b>CUPFERRON</b> .....	<b>243</b>
1. Exposure Characterization .....	243
1.1 Identification of the agent .....	243
1.2 Production and use .....	243
1.3 Measurement and analysis .....	244
1.4 Occurrence and exposure .....	244
1.5 Regulations and guidelines .....	245
2. Cancer in Humans .....	245
3. Cancer in Experimental Animals .....	245
3.1 Mouse .....	245
3.2 Rat .....	251
3.3 Synthesis .....	252
4. Mechanistic Evidence .....	252
4.1 Absorption, distribution, metabolism, and excretion .....	252
4.2 Evidence relevant to the key characteristics of carcinogens .....	253
4.3 Data relevant to comparisons across agents and end-points .....	253
5. Summary of Data Reported .....	256
5.1 Exposure characterization .....	256
5.2 Cancer in humans .....	256
5.3 Cancer in experimental animals .....	256
5.4 Mechanistic evidence .....	257
6. Evaluation and Rationale .....	257
6.1 Cancer in humans .....	257
6.2 Cancer in experimental animals .....	257
6.3 Mechanistic evidence .....	257
6.4 Overall evaluation .....	257
6.5 Rationale .....	257
References .....	258
 <b>LIST OF ABBREVIATIONS</b> .....	 <b>261</b>
 <b>ANNEX 1. Supplementary material for Section 1, Exposure Characterization</b> .....	 <b>263</b>
 <b>ANNEX 2. Supplementary material for Section 2, Cancer in Humans</b> .....	 <b>265</b>
 <b>SUMMARY OF FINAL EVALUATIONS</b> .....	 <b>267</b>